SAN CARLOS, Calif.--(BUSINESS WIRE)--IncellDx today announced it has been granted U.S. Patent No. 11,180, 491 by the U.S. Patent and Trademark Office (“USPTO”) for methods of treating coronaviruses including COVID-19 (the “Patent”). This patent underwent expedited review under the USPTO’s COVID-19 Prioritized Examination Pilot Program.
SAN CARLOS, Calif.--(BUSINESS WIRE)--IncellDx’s Chronic COVID Treatment Center (CCTC) (www.covidlonghaulers.com) and ARISE™ MD Integrative Medicine & Surgery announced today a new partnership to evaluate CCR5 antagonists and statins as a potential therapeutic treatment approach for chronic COVID, also known as long COVID or post-acute sequelae of COVID-19 (PASC).